Heman Lapman Chao
Direktor/Vorstandsmitglied bei Helix Immuno-Oncology SA
Profil
Heman Lapman Chao is a Member-Supervisory Board at Helix Immuno-Oncology SA. He previously worked as Director, Chief Executive & Scientific Officer at Helix BioPharma Corp.
from 2017 to 2021.
Prior to that, he was the President of Sensium Technologies, Inc. from 2004 to 2008 and a Manager from 1999 to 2002.
Dr. Chao earned a doctorate degree from Queen's University in 1994.
Aktive Positionen von Heman Lapman Chao
| Unternehmen | Position | Beginn |
|---|---|---|
Helix Immuno-Oncology SA
 Helix Immuno-Oncology SA Pharmaceuticals: MajorHealth Technology Helix Immuno-Oncology SA engages in the research and development in the area of biotechnology. It develops technology and products with applications in cancer immunotherapy. The company was founded in 2013 and is headquartered in Gliwice, Poland. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Heman Lapman Chao
| Unternehmen | Position | Ende |
|---|---|---|
| HELIX BIOPHARMA CORP. | Vorstandsvorsitzender | 01.09.2021 |
Sensium Technologies, Inc.
 Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | Präsident | 01.04.2008 |
Sensium Technologies, Inc.
Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | Corporate Officer/Principal | 01.06.2002 |
Ausbildung von Heman Lapman Chao
| Queen's University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HELIX BIOPHARMA CORP. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Sensium Technologies, Inc.
Sensium Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Helix BioPharma Corp., Sensium Technologies, Inc. researches and develops drugs and vaccines. Sensium Technologies was acquired by Helix BioPharma Corp. on December 10, 2002 for $3.83 million. | Commercial Services |
Helix Immuno-Oncology SA
Helix Immuno-Oncology SA Pharmaceuticals: MajorHealth Technology Helix Immuno-Oncology SA engages in the research and development in the area of biotechnology. It develops technology and products with applications in cancer immunotherapy. The company was founded in 2013 and is headquartered in Gliwice, Poland. | Health Technology |
